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Objective: The best way to manage both symptomatic and asymptomatic severe carotid stenoses has been thoroughly
demonstrated by large randomized clinical trials, but less is known about the natural history and management of the
contralateral asymptomatic internal carotid artery (ICA). This prospective study was undertaken to determine whether
disease progressed in the contralateral ICA of patients who had undergone carotid endarterectomy (CEA) and were
followed up clinically and by duplex ultrasound (US) scan.
Methods: The contralateral asymptomatic ICAs of 599 patients who had undergone CEA for severe carotid disease over a
10-year period were followed up clinically and with duplex US scan at 1 month and then every 6 months. ICA stenosis
was classified as mild (30%-49%), moderate (50%-69%), severe (70%-99%), or occlusion. Progression was defined as an
increase in ICA stenosis of 50% or more for ICAs with a less than 50% baseline lesion or as an increase to a higher category
if the baseline stenosis was 50% or more. End points of the study were the incidence of contralateral disease progression
and late neurologic events. Kaplan-Meier analysis was used to estimate freedom from disease progression and from
neurologic events. The relationship between progression and risk factors was also analyzed.
Results: Overall, disease progressed in 25.2% of patients (151/599) after a mean follow-up of 4.1 years. Disease
progressed in 34.3% of patients (101/294) with mild stenosis vs 47.9% of patients with moderate stenosis (47/98;
P  .016). Three additional patients with mild lesions at baseline progressed to severe lesions. The median time to
progression was 29.8 months for mild and 18.5 months for moderate stenoses (P .033). The rate of late neurologic
events referable to the contralateral ICA was 3.2% (19/599) for the entire series and 4.8% (19/392) for patients
with a 30% or greater ICA stenosis: these included 4 (0.7%) strokes and 15 (2.5%) transient ischemic attacks. All but
3 events (16.3%; 16/98) occurred in patients with disease progression from moderate to severe stenosis. Overall, 53
late CEAs were performed.
Conclusions: This prospective analysis has shown that disease progression in contralateral asymptomatic ICAs after CEA
is relatively common in patients with a diseased ICA at the baseline and strongly supports duplex US surveillance,
approximately every 6 months, in patients with more than mild disease. A baseline lesion is significantly predictive of
progression to severe stenosis, and progression from moderate to severe stenosis is strongly associated with neurologic
clinical events. No demographic or clinical factor proved useful in identifying patients likely to experience disease
progression. (J Vasc Surg 2007;45:516-22.)Large, randomized clinical trials have shown that ca-
rotid endarterectomy (CEA) significantly reduces the long-
term risk of stroke due to severe carotid artery disease
in symptomatic and asymptomatic patients.1-4 Although
many studies have clearly documented the progression of
carotid plaque in unoperated asymptomatic patients,5-7 the
incidence of contralateral asymptomatic disease progres-
sion after ipsilateral CEA and the frequency with which
such progression correlates with neurologic events have
been examined in fewer studies and with mixed find-
From the Vascular Surgery Section of the Geriatric Surgical Clinic, Depart-
ment of Surgical and Gastroenterological Sciences,a Department of Neu-
rological Sciences,b and Geriatric Surgical Clinic, Department of Surgical &
Gastroenterological Sciences,c University of Padua, School of Medicine.
Competition of interest: none.
Reprint requests: Enzo Ballotta, MD, Vascular Surgery Section of the
Geriatric Surgical Clinic, Department of Surgical & Gastroenterological
Sciences, University of Padua, School of Medicine, Second Floor, Osped-
ale Giustinianeo, Via N. Giustiniani, 2, 35128 Padova, Italy (e-mail:
enzo.ballotta@unipd.it).
0741-5214/$32.00
Copyright © 2007 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2006.11.011
516ings.8-16 The variability of the resulting picture can be
attributed mainly to the definition of disease progression,
the methods used to report events, and the duration of the
follow-up. Whereas some investigators define progression
as any change in a carotid lesion to a higher degree of
stenosis,8-10 others call it progression only when the steno-
sis reaches a 50% to 79% (or more) narrowing of the
lumen.11,12 The concept of progression used in various
studies consequently seems to be somewhat contrived.
Similarly, although disease progression does not necessarily
correlate with the development of neurologic events in
some studies,13,14 in others there are no reliable data re-
garding the onset of symptoms during follow-up.15,16
Close monitoring of the contralateral internal carotid
artery (ICA), based on serial duplex ultrasound (US) scan,
in patients who have undergone CEA with a view to
identifying lesions that would otherwise go unnoticed has
yielded conflicting conclusions, ranging from the convic-
tion that duplexUS scan follow-up has a minimal predictive
power17 to the recommendation for its widespread appli-
cation.18 We designed this prospective study to ascertain
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patients who had undergone CEA and were being prospec-
tively followed up, both clinically and with duplex US scan.
SUBJECTS AND METHODS
All patients who underwent CEA at our institution over
a 10-year period (1995-2004) for symptomatic or asymp-
tomatic ICA disease, according to the recommendations of
theNorth American Symptomatic Carotid Endarterectomy
Trial (NASCET)1 and the Asymptomatic Carotid Athero-
sclerosis Study (ACAS),3 and who had less than 70% con-
tralateral ICA stenosis were prospectively followed up by
clinical examination and duplex US surveillance. Informed
consent was obtained from all patients involved, and the
study was approved by the ethics committee of our institu-
tion. Details of the surgical procedure have been published
elsewhere.19 Patients with contralateral ICA occlusions at
preoperative duplex US scan or with symptomatic or
asymptomatic contralateral ICA stenoses 70% or greater,
for whom bilateral CEA was planned at the baseline duplex
US scan, were excluded from the analysis.
Preoperative, postoperative, and follow-up visits were
conducted by two experienced neurologists. Preoperative
duplex US scan was performed in all patients considered for
CEA, and the contralateral ICA was routinely imaged. The
diagnosis of an ICA lesion was based on preoperative digital
subtraction angiography during the earlier part of this study
(used with decreasing frequency over the years), whereas
duplex US scan was the only preoperative ICA imaging study
performed in most patients from mid 1998 onward, com-
bined in selected patients (patients who either had a pseudo-
occlusion on duplexUS scan or a stenosis of the ICA intracra-
nial segment detected by transcranial Doppler sonography)
with magnetic resonance angiography, contrast-enhanced
magnetic resonance angiography, or digital subtraction an-
giography.
All duplex US studies were performed on an ATL
Ultramark 9 HDI system (Advanced Technology Labora-
tories, Bothell, Wash) and interpreted by two experienced
technologists. During the follow-up period, duplex US
scan was performed 1, 6, and 12 months after surgery and
once every 6 months thereafter. If a patient missed the
6-month duplex US scan but showed progression on the
12-month scan, the progression was attributed to the latter
time. The cutoff on carotid duplex US scans was set at a
30% carotid lumen narrowing. Stenosis with a 30% or
greater reduction in diameter was stratified into subgroups
(mild, 30%-49%; moderate, 50%-69%; severe, 70%-99%;
and occlusion) by combining criteria validated yearly at our
laboratory by internal quality control20,21 with criteria de-
termined by external review22-24 and validated by numer-
ous vascular laboratories (Table I). As reported else-
where,20,21 these criteria revealed a satisfactory correlation
with the angiographic findings when the degree of stenosis
was calculated as the percentage of diameter reduction, in
compliance with the NASCET1 and ACAS3 methods.
Transcranial Doppler sonography was routinely performed
before surgery by an experienced neurosonographer to ruleout any intracranial lesions and, particularly, any stenosis of
the middle cerebral artery ipsilateral to the ICA disease.
End points of the study were disease progression of the
contralateral ICA and the relationship between neurologic
symptoms (contralateral hemispheric transient ischemic at-
tacks [TIAs] or stroke) and the degree of stenosis of the
contralateral ICA. In agreement with Raman and associ-
ates’ criteria,15 we defined any progression as an increase in
ICA stenosis of 50% or greater for ICAs with a baseline
lesion less than 50% or an increase to a higher category of
stenosis if the baseline lesion was 50% or greater. The
transition from no stenosis (0%-29%) to mild stenosis was
therefore not classified as progression, whereas all other
increases in severity were considered as progression.
All patients who met the inclusion criteria were given
the best available medical therapy and aspirin (one 100-mg
tablet per day), or, if aspirin was contraindicated, they were
given clopidogrel 150mg initially and then 75mg daily. All
patients were instructed to call their physician if they devel-
oped symptoms. Late contralateral CEA was performed if
the lesion progressed to severe stenosis, according to du-
plex US scan and confirmed by further imaging studies, or
if the patient became symptomatic. Clinical presentation
was always classified by the consultant neurologist as TIA
(ie, temporary hemispheric symptoms lasting 24 hours,
with complete recovery), amaurosis fugax (transient mon-
ocular visual loss), or stroke (minor [minimal, stabilized
focal neurologic deficit of acute onset and persisting 24
Table II. Baseline characteristics
Variable Data
No. patients 599
Mean age, y (SD; range) 71 (7.12;35-91)
No. men (%) 372 (62.1)
Risk factors, n (%)
Hypertension 342 (57.1)
Hyperlipidemia 258 (43.1)
Current or past smoking 405 (67.6)
Diabetes 198 (33.0)
Cardiac ischemic disease 267 (44.6)
Table I. Duplex scan criteria for carotid artery stenosis
ICA
stenosis (%) PSV (cm/s) EDV (cm/s)
ICA/CCA
PSV
0-29 100 40
30-49 110-130 40
50-59 130 40 3.2
60-69 130 40-110 3.2-4.0
70-79 210 110-140 4.0
80-99 210 110-140 4.0
Occlusion Undetectable
flow
Undetectable
flow
Not applicable
ICA, Internal carotid artery; PSV, peak systolic velocity; EDV, end-diastolic
velocity; ICA/CCA PSV, internal carotid artery to common carotid artery
PSV ratios.hours, but not causing disability or any significant impair-
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30 days and inducing a change in lifestyle]).
Statistical analysis was performed with Student t tests
for continuous data and with 2 analysis or Fisher exact
tests (two tailed), as appropriate, for categorical data.
Kaplan-Meier life-table analysis was used to estimate free-
dom from disease progression, onset of neurologic events,
and survival rates by using the log-rank test for comparison.
Progression and neurologic events were considered censor-
ing events for the ICA involved, in the same way as death is
treated in a mortality rate study. Significance was inferred at
P  .05. The incidence of disease progression was ana-
lyzed in association with recorded risk factors. Cox propor-
tional hazards multivariate analysis was used to determine
which factors with statistical or marginal significance at the
univariate analysis could influence disease progression.
RESULTS
During the study period, a total of 777 patients under-
went 848 CEA procedures, all performed by the same
surgeon. Overall, the perioperative mortality and stroke
rates were 0% and 0.6% (5/848), respectively. Eighty-nine
patients (11.4%) with contralateral ICA occlusions and 71
patients (9.1%) for whom bilateral CEA was planned at the
time of the first preoperative duplex US scan were excluded
from this analysis. Eighteen patients (2.3%) were lost to
follow-up, bringing the total study group down to 599
patients. In this group, the perioperative stroke rate de-
creased to 0.5% (3/599); 2 strokes (1 major and 1 minor)
were excluded because they occurred in the hemisphere
contralateral to the revascularized ICA and ipsilaterally to
an occluded ICA.
Patients’ demographic data and risk factors are summa-
rized in Table II. All of the recommended duplex US scans
were performed in 557 (92.9%) of 599 patients. The mean
number of carotid duplex US scans performed in the series as
a whole was 4 (range, 2-16). Although transition from a
normal ICA at baseline to mild stenosis was noted in 12
(5.8%) of 207 patients, there was an overall disease progres-
sion in 151 (25.2%) of 599 patients after a mean follow-up of
4.1 years (range, 6-122 months; Table III). Lesions pro-
Table III. Median and mean disease progression times an
Baseline contralateral
ICA lesion (%)
Arteries, n
(%)
Progression to one
category higher (n) c
0 (normal) 207 (34.5) 12*
30-49 (mild) 294 (49.1) 101†
50-69 (moderate) 98 (16.4) 47†
70 (severe) 0 0
Total 599 (100) 148
ICA, Internal carotid artery; TIA, transient ischemic attack.
*An evolution from no to mild stenosis was not considered progression.
†P  .016 (2 test).
‡The number of lesions progressing from mild to moderate and then to sev
17 months after entering the moderate category.
§P  .033 (t test).gressed frommild tomoderate stenosis in 101 (34.3%) of 294patients and from moderate to severe in 47 (47.9%) of 98
patients (P .016). Three additional lesions (1%) among the
294mild baseline stenoses progressed frommild to moderate
and then to severe stenosis within a mean of 31 months after
the baseline duplex US scan and 17 months after joining the
moderate stenosis category, so theywere counted in the severe
stenosis subgroup and considered for surgical correction. All
50 patients with severe stenosis underwent uneventful CEA.
There were no cases of progression from severe stenosis to
subocclusion or occlusion (Table III).
Median and mean times to progression in the groups
are shown in Table III. The median time to progression was
29.8 months for mild and 18.5 months for moderate
stenoses (P  .033).
Kaplan-Meier analysis showed that freedom from any
disease progression at 1, 3, 5, 7, and 10 years was 93.4%,
70.6%, 57.3%, 52.3%, and 52.3%, respectively, whereas
freedom from progression for patients with mild baseline
stenosis at 1, 3, 5, 7, and 10 years was 97.3%, 77.2%, 62.1%,
57.8%, and 57.8%, respectively, and for patients with mod-
erate baseline stenosis at 1, 3, 5, 7, and 10 years was
81.6%, 50.6%, 42.6%, 37.7%, and 37.7%, respectively
(Fig 1). A statistically significant difference emerged
when freedom from disease progression was compared
between patients with mild vs moderate baseline stenosis
( P  .0001; Fig 1).
The incidence of late neurologic events referable to the
unoperated ICA was 3.2% (19/599 patients) for the entire
series and 4.8% (19/392) for patients with a diseased
(30% stenosis) ICA: these included 4 strokes (0.7%) and
15 TIAs (2.5%) (Table III). Sixteen (84.2%) of 19 neuro-
logic events occurred in patients with disease progression
from moderate to severe stenosis (16/98; 16.3%). The
remaining three events (one minor stroke and two retinal
TIAs) were not associated with disease progression (one
mild baseline lesion and two moderate baseline lesions,
respectively). All remaining strokes were minor and oc-
curred in patients with moderate baseline lesions that pro-
gressed to severe stenoses. Kaplan-Meier analysis showed
that freedom from neurologic events for patients with a
diseased ICA at 1, 3, 5, 7, and 10 years was 99.2%, 95.5%,
ptoms
ession to two
ies higher (n)
Median time
(mo)
Mean time
(mo)
No. Symptoms
(stroke  TIA)
0 0
3‡ 29.8§ 35.2 1  0
0 18.5§ 25.6 3  15
0
3 19 (4  15)
nosis in a mean of 31 months after the baseline duplex ultrasound scan andd sym
Progr
ategor
ere ste93.4%, 92%, and 92%, respectively, whereas freedom from
t each
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from moderate to severe stenosis at 1, 3, 5, 7, and 10 years
was 96.9%, 80.5%, 75.1%, 72%, and 72%, respectively
(Fig 2). Thus, 53 patients (50 patients whose stenoses
Fig 1. Kaplan-Meier curves show the probability of fre
moderate stenosis, and from progression from moderate
freedom from disease progression at 10 years. The standa
range of standard errors for any progression is 0% to 3.9%
to severe stenosis is 0% to 8.2%. Raw numbers of the pa
each time point are provided below the figure.
Fig 2. Kaplan-Meier curves show the probability of free
carotid disease and for those with a moderate stenosis
represent rates of freedom at 10 years. The standard erro
of standard errors for 30% or greater carotid disease is 0%
numbers of the patients at risk analyzed in each subset aprogressed to severe lesions plus 3 based exclusively ontheir symptoms; 8.8% of the entire series) underwent un-
eventful CEA. Three additional strokes unrelated to any
ICA disease were recorded in this series: one was cardioem-
bolic (a fatal stroke in a patient with atrial fibrillation of
from any progression, from progression from mild to
vere stenosis. Percentages on the right represent rates of
ror is less than 10% at each time point in each curve. The
ild to moderate stenosis is 0% to 4.2%, and for moderate
at risk of disease progression analyzed in each subset at
from neurologic events for patients with 30% or greater
rogressed to a severe lesion. Percentages on the right
ss than 10% at each time point in each curve. The range
% and for moderate to severe stenosis is 0% to 7.8%. Raw
time point are provided below the figure.edom
to se
rd er
, for m
tientsdom
that p
r is le
to 2.3recent onset), and two were lacunar.
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whole. The cause of late death was primarily cardiac related
(n 19). The overall rates of freedom from death at 1, 3,
5, 7, and 10 years were 99.9%, 97.8%, 93.1%, 92.7%, and
88.6%, respectively. Univariate analysis of various risk factors
and disease progression is summarized in Table IV.
Diabetes mellitus and arterial hypertension correlated
with a statistically higher incidence of disease progression,
whereas only a marginal significance was noted for patients
with a history of smoking. Cox analysis showed no signifi-
cant influence of the risk factors considered (diabetes mel-
litus, arterial hypertension, and smoking) on disease pro-
gression, however.
DISCUSSION
Stroke prevention is the goal in the management of
patients with ICA disease.1-4 The recently published results
of the largest randomized trial on asymptomatic ICA dis-
ease4 have further confirmed the already well known advan-
tages of CEA over medical treatment for asymptomatic
patients with severe ICA lesions.3 The Asymptomatic Ca-
rotid Stenosis Study,25 which considered findings from
randomized trials and prospective cohort studies on pa-
tients with ICA disease, has also shown a considerably
higher 3-year risk of ischemic stroke ipsilateral to a severe
symptomatic lesion than to a severe asymptomatic lesion
(21% vs 8%), whereas the 8-year risks were comparable
(25% vs 20%), thus demonstrating that the risk of stroke
ipsilateral to a severe asymptomatic stenosis increases lin-
early with time and suggesting that it is inappropriate to
discriminate between “asymptomatic” and “symptomatic”
patients in the best management strategies for reducing
stroke risk in the long term. The findings of these studies
therefore support carotid duplex US surveillance for pa-
tients who might be at a higher risk of ICA disease progres-
sion, such as those who have undergone contralateral
Table IV. Univariate analysis of risk factors and carotid di
Risk factor
Age (y) Mean (SD)
Sex Female
Male
Smoking Yes
No
DM Yes
No
Hypertension Yes
No
Cardiac disease Yes
No
Cholesterol (mg/dL) Mean (SD)
Total
Low-density lipoprotein
High-density lipoprotein
Triglycerides (mg/dL) Mean (SD)
DM, Diabetes mellitus.
Data are n (%) unless otherwise noted.
P values are based on *t and †2 tests.CEA.8,11,13To our knowledge, this is the largest prospective
study to date with a lengthy follow-up using duplex US
surveillance on contralateral asymptomatic ICAs after
CEA. This study revealed contralateral disease progres-
sion in more than 1 in 4 patients (151/392) with a
diseased ICA at baseline, but only a third of the lesions
(50/151) progressed to severe stenosis. No lesion pro-
gressed from more than 70% stenosis to a more severe
stenosis or occlusion because all patients whose stenosis
was found to be severe during duplex US follow-up were
considered candidates for CEA and crossed over to the
surgical group, thus preventing any further disease pro-
gression. This might be regarded as a limit of this anal-
ysis, in that we failed to ascertain the true natural history
of asymptomatic lesions, but it would have been uneth-
ical to continue to follow patients up clinically if CEA
was indicated.
Our findings that the incidence of disease progression
was significantly higher in patients with a higher degree of
stenosis (P .016) and that progression from moderate to
severe stenosis took significantly less time than progression
from initially mild to moderate stenosis (P  .033) are
consistent with other reports.9,13-15 In the AbuRahma and
colleagues’ series14 of 420 patients followed up for a mean
41months after CEAwith an average of 3 duplex US scans,
contralateral ICA disease occurred statistically more fre-
quently in patients with moderate than with mild ICA
lesions (47% vs 36%; P  .003), and the median time to
progression was twice as fast for moderate than for mild
stenoses (12 vs 24 months, respectively; P  .035). Simi-
larly, Raman et al15 found an overall annual rate of disease
progression in the contralateral ICA of 8.3% and an annual
rate of progression to severe stenosis or occlusion of 4.4% in
a cohort of 233 patients, 3 in 4 of whom had either no or
only mild ICA lesions at baseline duplex US scan and were
followed up for a mean 27 months after CEA, with an
progression
o progression Progression P value
66.7 (9.2) 65.8 (9.8) .373*
174 (76.6) 53 (23.4) .413†
274 (73.6) 98 (26.4)
294 (72.6) 111 (27.4) .073†
154 (79.4) 40 (20.6)
136 (68.7) 62 (31.3) .016†
312 (77.8) 89 (22.2)
244 (71.3) 98 (28.7) .025†
204 (79.4) 53 (20.6)
198 (74.1) 69 (25.9) .749†
250 (75.3) 82 (24.7)
32.6 (34.1) 231.8 (34.2) .802*
50.2 (25.9) 150.2 (27.9) .991*
42.9 (11.4) 42.3 (9.9) .514*
97.7 (105.6) 197.2 (95.7) .967*sease
N
2
1
1average of 3.7 duplex US scans.
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of predicting disease progression, however. This is consistent
with Spence and associates’ observation26 that ICA stenosis
was much less useful than total plaque area in studies on
carotid atherosclerosis. Indeed, total plaque area was more
strongly associated with traditional risk factors than ICA ste-
nosis: a likely reason is that ICA stenosis is an expression not of
plaque progression, but of plaque rupture.26
Symptoms referable to the contralateral ICA were rela-
tively infrequent in our series as a whole (3.2%). However,
more than 80% (16/19) of neurologic events occurred in
patients with disease progression from moderate to severe
stenosis, andmore than a third of the patients who underwent
late contralateral CEA (35.8%; 19/53) were symptomatic.
Even though we found a strong relationship between the
occurrence of neurologic symptoms and progression from a
moderate to severe lesion (P  .001), the onset of symp-
toms was not compulsorily related to disease progression:
there was no evidence of disease progression in the three
patients with a diseased ICA at baseline who underwent
CEA on the basis of their symptoms alone. Other authors
have reported symptoms developing in patients with and
without contralateral disease progression.8,13 Norrving
et al8 found a more than fourfold incidence of neurologic
symptoms in patients with contralateral progression to
clinically significant lesions by comparison with patients
showing no evidence of disease progression (18% vs 4%,
respectively). Similarly, Roederer et al.13 found a signifi-
cantly higher incidence of symptoms in patients with con-
tralateral disease progression than in patients whose arteries
remained stable on duplex US surveillance (18% vs 8%,
respectively). Whether the low number of clinical ischemic
events occurring in our series correlates with what some
believe to be a protective effect of contralateral CEA or why
symptoms rarely develop in patients with no evidence of
disease progression are questions that remain to be an-
swered and might warrant further investigation.
CONCLUSIONS
This prospective analysis has shown that disease pro-
gression in contralateral asymptomatic ICA after CEA is
relatively common in patients with a diseased ICA at base-
line and strongly supports duplex US surveillance approxi-
mately every 6 months in patients with more than mild
disease. The baseline lesion is a significant predictor of
progression to severe stenosis, and progression from a
moderate to severe lesion is strongly associated with neu-
rologic events. No demographic or clinical factor proved
useful, however, in identifying patients likely to experience
disease progression.
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